Carboplatin (NSC 241240)

For research use only.

Catalog No.S1215 Synonyms: JM-8, CBDCA

75 publications

Carboplatin (NSC 241240) Chemical Structure

CAS No. 41575-94-4

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Selleck's Carboplatin (NSC 241240) has been cited by 75 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[6]
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmyMVI26oDLzszN NXnUZYxzPzJiaB?= MkHobY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|N{GwOUc,OjZzM{exNFU9N2F-
Tca8113/CBP  MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHizOYwzNTJ34pEJ{txO M2XTdlczKGh? NVjFPGM2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M4\xe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NVA2Lz5{NkGzO|ExPTxxYU6=
Tca8113/PYM  NH3uc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuyMVI26oDLzszN NXzoU|BtPzJiaB?= MUXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MlrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{exNFUoRjJ4MUO3NVA2RC:jPh?=
SKOV3 NX;kNJMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XUelYxKG2pL33s MXGxMVUh\A>? NYXENmw4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= NILab5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|A1Oyd-Mk[xN|cxPDN:L3G+
SKOV3 NVnTW3FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVywMVQh|rypL33s MlTnNlQwPDhxN{KgbC=> MX7pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NHTqOJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOVI4Oyd-Mk[xNlUzPzN:L3G+
SKOV3 M{j4O2Fxd3C2b4Ppd{BCe3OjeR?= M4rxbFIh|rypL33s MWq0PEBp MVnpcoR2[2W|IHHwc5B1d3Orcx?= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUK3N{c,OjZzMkWyO|M9N2F-
OSA MmfpR4xwdm:pZX7pZ{BCe3OjeR?= M1TjSVIvPS93IN88US=> NVTL[oZwemW|dXz0d{BqdiCub4fldkBkd2yxbomg[o9zdWG2aX;uJIF{KGOxbYDhdoVlKHSxIHXpeIhmeiCETVmxJJNqWk6DIITy[YF1dWWwdB?= Mn7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUC2NlAoRjJ4MUGwOlIxRC:jPh?=
A549 NGm1eXZHfWO2aX;uJGF{e2G7 NUO4flc5OC9{NT:1NEDPxE1? Mmm5NlQhcA>? NVPQT|Zv\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> NFTkPY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO|MyPyd-MkW5NVc{OTd:L3G+
H1975 MXjGeYN1cW:wIFHzd4F6 MnzFNE8zPS93MDFOwG0> MWeyOEBp NVK0[m5[\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> MnG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N|E4RC:jPh?=
A549 M3r5b2Z2[3Srb36gRZN{[Xl? NX;kemlGOC9{NT:1NEDPxE1? MUGyOEBp MXj1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44> MorMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N|E4RC:jPh?=
H1975 NIXIS21HfWO2aX;uJGF{e2G7 NFvTPFcxNzJ3L{WwJO69VQ>? NGrCN2YzPCCq NV[zdWh[fXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
A549 NVTZRnpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;Wblc6OjVizszN NF;tOFgzPCCq MVnpcohq[mm2czDj[YxtKGe{b4f0bC=> NIPB[W49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO|MyPyd-MkW5NVc{OTd:L3G+
H1975 M4DSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3e3WFI2KM7:TR?= NVzOcWZUOjRiaB?= MlvGbY5pcWKrdIOgZ4VtdCCpcn;3eIg> MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N|E4RC:jPh?=
MDA-MB-231 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37xT|AuOjJyIN88[{9udA>? MlXsO|IhcA>? NVTx[oMyUUN3MNMgQUA5PiEQvF2= NX[xelI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N|c3QTFpPkK1PFM4PjlzPD;hQi=>
T47D MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSwMVIzOCEQvHevcYw> MmntO|IhcA>? NED5Zm9KSzVywrC9JFQ5NjlizszN M1TabVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO3OlkyLz5{NUizO|Y6OTxxYU6=
LCTCC MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ntdmlEPTB;Mz645qCKyrWP NGTHbFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N|E3Pyd-MkW3O|MyPjd:L3G+
MCTCC NH\5TIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT2TYJKSzVyPUKuPQKBkcL3TR?= Mnn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{OxOlcoRjJ3N{ezNVY4RC:jPh?=
MegTCC NIrSeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrtWoZMUUN3ME20MlHjiIoEtV2= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MonoTCC M{PDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG3RYxKSzVyPUWuOwKBkcL3TR?= MmO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{OxOlcoRjJ3N{ezNVY4RC:jPh?=
MCF7 Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H6XFIxKM7:TR?= MkHuO|IhcA>? MkX6bY5lfWOnczDj[YxtKGSnYYToJI9nKEiSMd8yMYRmeGyndHXkJG1ETjdiY3XscJM> NUXPNVlnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlkxOjVpPkK1O|Y6ODJ3PD;hQi=>
A-549  M2Ho[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSwMlUh|ryP NVjC[G9pOjRiaB?= NHfGTGZFVVORwrC= MVPpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUW2PVAoRjJ3N{W1OlkxRC:jPh?=
A-549  M2P6NGFxd3C2b4Ppd{BCe3OjeR?= MlfLNE42KM7:TR?= M1XhTVQ5KGh? NVvCPWJUTE2VT9Mg NVTBTGdUe2ixd4Og[YFzdHliYYDvdJRwe2m|IH\lZZR2emW|IHnuZ4x2\GmwZzDicIVj[mmwZzDhcoQh[2i{b33heIlvKGOxbnTlcpNifGmxbh?= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NU[5NEc,OjV5NUW2PVA9N2F-
A-549  M{f0TGZ2[3Srb36gRZN{[Xl? NX3r[IdjOC53IN88US=> M4frd|Q5KGh? NXz6NXVnTE2VT9Mg M2HucpNpd3e|IHHi[ZJz[W62IH3pZ5JwfHWkdXzlJIRqe3K3cITpc44> M2PkUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W1OlkxLz5{NUe1OVY6ODxxYU6=
A-549  MUXGeYN1cW:wIFHzd4F6 MoLhNE42KM7:TR?= NX;WUJREPDhiaB?= NUXhSY12TE2VT9Mg MUXpcohq[mm2czDv[kBk\WyuIH3p[5JifGmxbtMg MlrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUW2PVAoRjJ3N{W1OlkxRC:jPh?=
RMG-1 NXTkWYFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ6LkigxtEhOy54IH3nM2w> Mnn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
FN-RMG-1 M3;ycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;z[FJKSzVyPUSwMlUhyrFiND6yJI1oN0xMIN88US=> MoDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
RMG-1-hFUT NVe5enc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTV6LkGgxtEhOi52IH3nM2w> NFTlO4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyOlkyOyd-MkW3NlY6OTN:L3G+
FN-RMG-1-hFUT M3jaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XJ[2lEPTB;MUG4MlghyrFiMUOuPEBu\y:O Mki3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
CHP-134  NELjfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXwelEyKM7:TR?= M37XZ2ROW00EoB?= M2e5colvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? MnvRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUi0OlMoRjJ3NkW4OFY{RC:jPh?=
IMR-32 M1yycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDpVYQyKM7:TR?= MkfpSG1UV8Li NVjUO|RkcW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
CHP-134  MU\GeYN1cW:wIFHzd4F6 MYOxNEDPxE4EoB?= NVvVSos2TE2VT9Mg M1rRNIlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy M{HpSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW4OFY{Lz5{NU[1PFQ3OzxxYU6=
IMR-32 M4XncmZ2[3Srb36gRZN{[Xl? M3;EWlExKM7:TdMg NEDUV25FVVORwrC= NY\QcZJRcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? NH;HVmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PFQ3Oyd-MkW2OVg1PjN:L3G+
A549 NVXUOWZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHXV3kxNjJvNECwNEDPxE1? NEHHXpI4OiCq NGTkXYNKSzVyPUGyOkDDuSB3LkCg{txO Mof6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkWyOFMoRjJ3NkK1NlQ{RC:jPh?=
A549/CDDP Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\nTnNqOC5{LUSwNFAh|ryP M3zUVlczKGh? M3m4S2lEPTB;MkSwxsDDucLiNEWuO{DPxE1? M4XSXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1NlQ{Lz5{NU[yOVI1OzxxYU6=
H460  NWXoeXE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWwNlQhcA>? NHrKPYFFVVOR MkXCTWM2OD15Lkmg{txO NIjmPZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5PVk6PSd-MkW1PVk6QTV:L3G+
H460  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi0O{46KM7:TR?= MkLXNlQhcA>? NFvz[oxFVVOR MYfzbI94eyCjIILh[Ilwe2Wwc3n0bZpqdmdiZX\m[YN1KHSxIGitdoF6ew>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7OUm5OUc,OjV3OUm5PVU9N2F-
NRK-52E MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWG3NuKhcMLi MWjJR|UxRTFyMDFCtUAyOi57IN88US=> NWHXdnFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB|PD;hQi=>
RGE NEDYemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jiSVczyqCqwrC= MVfJR|UxRTJ{INMxJFcvPCEQvF2= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4NU[wN{c,OjV3NkW2NFM9N2F-
NRK-52E M2jDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYC3NuKhcMLi NX7OTW9jUUN6ME2xO|khyrFiOT61JO69VQ>? NWjXXXd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB|PD;hQi=>
RGE NUTrdYx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTPO|LDqGkEoB?= MYPJR|gxRTZ|INMxJFcvPCEQvF2= Mn;mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
SK-OV-3 M4jUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DGdlczKGh? M3ntbGlEPTB;MUC0Mlgh|ryP MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
ES-2 M1vY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm3NkBp NHfoSYZKSzVyPUG0MlYh|ryP M3XFRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
OVCAR-8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnM[pM4OiCq NF\scIlKSzVyPUm2MlAh|ryP MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
3AO NEjRZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[3NkBp NXjZXIN3UUN3ME22N{41KM7:TR?= NFu5UJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyNFE{Oid-MkW1NlAyOzJ:L3G+
A2780 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUO3NkBp MW\JR|UxRTF2NT63JO69VQ>? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN|I9N2F-
SW626 NUnwZ5BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXobIs4OiCq MVfJR|UxRTl5LkCg{txO NXHBXXdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
OVCAR-3 MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf0O|IhcA>? M{LqXmlEPTB;M{KuOkDPxE1? NX36VHl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
A549 NWG2b2c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHSzSJRKSzVyPUG1NU42PiEEsTC1N{4xPiEQvF2= NX\pbotlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
4T1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTh2Lk[yJOKyKDNyLkC1JO69VQpizszN NELYZm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q3OSd-MkWyO|c1PjF:L3G+
BALB/3T3 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[5d4VKSzVyPUG0MlMxKMLzIE[uOlgh|ryP MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
B16 Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7XVFhNUUN3ME22OE4{OCEEsTC2MlgyKM7:TR?= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
DU 145 M{fWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTN3LkC0JOKyKDF5LkW0JO69VQ>? NWPrbpVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
FaDu M4\1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTR3LkO5JOKyKDFzLkWwJO69VQ>? M3vydlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O|Q3OTxxYU6=
HCV-29T MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL4fXdrUUN3ME20PE42PyEEsTCyNk41QSEQvF2= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
HL-60 M1rHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnwRpNKSzVyPUGxMlExKMLzIESuOFch|ryP NVTlbJR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
HT-29 NV3mNZFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTuTWM2OD16OT6xOkDDuSBzOD64OkDPxE1? MoL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
H146 NFm3XVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTR7LkdCtVE{NjFizszN NVq2WnZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
H187 NIHFVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXuTWM2OD1zMj63xtEzNjdizszN NFHmZZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
H128 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;ob|BmUUN3ME2xNFYvPMLzOT62JO69VQ>? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H69 NGLQblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTd4LkpCtVI4NjhizszN MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H209 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfD[3NKSzVyPUK1PE4yyrF7OT64JO69VQ>? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
DMS153 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjpWpJKSzVyPUW3MljDuTlwMjFOwG0> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H526 NFHqfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fUe2lEPTB;Nz6yxtEyNjdizszN NIPHUGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
DMS114 NU\YeXdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHwTXRKSzVyPUi1MljDuTF{Lkig{txO NWLzcplyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
DMS53 M4LKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF2Nj6yxtE{Pi52IN88US=> Mn75QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
HeLa MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvT[FJvPS16MDFOwG0> MkLsbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M1\D[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC5N|YxLz5{NUGwPVM3ODxxYU6=
MCF-7 MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWG1MVgxKM7:TR?= NEXm[pVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUO2NEc,OjVzMEmzOlA9N2F-
MDA-MB-231 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:1MVgxKM7:TR?= M1rQWYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MoPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzOlAoRjJ3MUC5N|YxRC:jPh?=
CaOV3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jRRVczKGh? MoLNTWM2OD16Nj6xJO69VQ>? MoK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
OVCAR-3 NEjaZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\ZPZRrPzJiaB?= NXnnb4ZyUUN3ME2xO|kvPSEQvF2= M3\3RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
OVCAR-5 NX\lTIl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL2d3o4OiCq M37oXWlEPTB;N{WuO{DPxE1? M1zWT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
SKOV-3 M4fNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn3ZY5wPzJiaB?= NFfRT2VKSzVyPUWwOEDPxE1? M{m1S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
OVCAR-4 NGPlcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPCO|IhcA>? NW\NXpZOUUN3ME2yPVAvPiEQvF2= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
OVCAR-8 MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny1O|IhcA>? Mni5TWM2OD14OUCuNkDPxE1? M1vub|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
MA148 M4GyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LWTFI1KGh? NGXzN4hKSzVyPUizMlbjiIoEsfMAjVEvPCEQvHevcYw> M2HGXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
A549 Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy3OZJNOjRiaB?= MlfoTWM2OD15N{[uNQKBkcLz4pEJNU46KM7:Zz;tcC=> Mn71QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
MDA-MB-231 NFHYRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;vV5ozPCCq M1ezTWlEPTB;N{S4MlDjiIoEsfMAjVEvOSEQvHevcYw> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
NCI-ADR/RES  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{izUlI1KGh? NIO3U5hKSzVyPUG3OVMvOOLCidMx5qCKPC52IN88[{9udA>? NXnTfmhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
MA148 NInxNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof5OFghcA>? NHq0Z2pKSzVyPUK4MlHjiIoEsfMAjVEvOCEQvHevcYw> M1;RT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
A549 NFPHfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLocVZIPDhiaB?= NHW0V5pKSzVyPUGxPE4x6oDLwsJihKkyNjJizsznM41t M1fZWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MDA-MB-231 NY[wV5ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfROFghcA>? M{XTNGlEPTB;MUizMlDjiIoEsfMAjVEvOiBizsznM41t M{nIeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
NCI-ADR/RES  NUC2SIZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXYSog1QCCq NWntU3RFUUN3ME2xPVMvOOLCidMx5qCKOS57IN88[{9udA>? M1XmbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MA148 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV63NkBp MV;JR|UxRTF|LkhihKnDueLCiUGuNkDPxGdxbXy= Ml:yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWO3NkBp MWHJR|UxRTZ2LkRihKnDueLCiUGuNUDPxGdxbXy= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
MDA-MB-231 M3vLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HrZ|czKGh? MXXJR|UxRTl7LkZihKnDueLCiUGuNUDPxGdxbXy= MojMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
NCI-ADR/RES  M1zOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGCw[mY4OiCq M2j6SGlEPTB;M{euOQKBkcLz4pEJNU44KM7:Zz;tcC=> NW\ibllRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
A549 M13Ee2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[yWpJbPzJiaB?= MXnEUXNQ MkHXTWM2OD1zNUKuOFA6KM7:TR?= M3S1elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{KxN|I{Lz5{NEeyNVMzOzxxYU6=
NCI-H157 MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XJ[lczKGh? NFy2[5VFVVOR MW\JR|UxRTh7Lkm3O{DPxE1? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{MUOyN{c,OjR5MkGzNlM9N2F-
PC9 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHPeZRKPzJiaB?= NEPQdo5ISzVyPUexMlbDuTlwNTFCuW0> NH7QdJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[xPFgxQSd-MkS2NVg5ODl:L3G+
A549  NH7jNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTnO|IhcA>? NG\6PHZISzVyPUGzOuKyOzFwNjFCuW3DqA>? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzOEiwPUc,OjR4MUi4NFk9N2F-
PC9 NEHlN3lCeG:ydH;zbZMhSXO|YYm= NUPpU4p[OTByINM1US=> MoXPO|IhcA>? Ml;WbY5lfWOnczDhdI9xfG:|aYO= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzOEiwPUc,OjR4MUi4NFk9N2F-
A549  NH:5WmJCeG:ydH;zbZMhSXO|YYm= M2DoblExOCEEtV2= NGX2OlY4OiCq NVvCSHBWcW6mdXPld{BieG:ydH;zbZM> MlTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUi4NFkoRjJ2NkG4PFA6RC:jPh?=
A549 NYe3[nZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELkNZQzPCCq M2fCc2lEOTB;MT60O|Yhdk1? NYfBbmJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N|k3PDN5PD;hQi=>
H1299 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDabWtsOjRiaB?= NF7HTmxKSzFyPUCuOFQ{KG6P MkPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OU[0N|coRjJ2M{m2OFM4RC:jPh?=
HCC15 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnOzNlQhcA>? M1fiSGlEOTB;MD6zOFYhdk1? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7NkSzO{c,OjR|OU[0N|c9N2F-
H157 M2H4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmyOEBp Mn;kTWMyOD1yLkixJI5O MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7NkSzO{c,OjR|OU[0N|c9N2F-
A2780 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvFSplKSzVyPUG0MlDjiIoEsfMAjVEvPCEQvF2= M1;iUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=
A2780cisR M4ewNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTldWlmUUN3ME20PE466oDLwsJihKk{NjlizszN MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJyOU[5N{c,OjR{MEm2PVM9N2F-
A2780ZD0473R MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rzS2lEPTB;NkSuOwKBkcLz4pEJN{4zKM7:TR?= NYfD[ZdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNFk3QTNpPkK0NlA6Pjl|PD;hQi=>
SKOV-3 NXTCVYRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonyTWM2OD12Mz605qCKyrIkgJmzMlkh|ryP NY\xR4R2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNFk3QTNpPkK0NlA6Pjl|PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pChK-2 / Chk-2 ; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p38 / p38 / Cleaved PARP / PARP ; 

PubMed: 30049957     


A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋€𢡄�෋€䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemセ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄

30049957
Immunofluorescence
γH2AX ; 

PubMed: 24348048     


Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ

24348048
Growth inhibition assay
Cell viability ; 

PubMed: 24348048     


SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay. 

24348048
In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Dosages: ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage 2 years 4°C(in the dark) powder
Synonyms JM-8, CBDCA
Smiles C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04907968 Recruiting Drug: XMT-1536 (Upifitamab Rilsodotin)|Drug: Carboplatin Platinum-sensitive Ovarian Cancer (UPGRADE-A) Mersana Therapeutics|IQVIA Biotech June 11 2021 Phase 1|Phase 2
NCT04606914 Recruiting Drug: mirvetuximab soravtansine (MIRV; IMGN853) Ovarian Cancer|Fallopian Tube|Primary Peritoneal Cancer University of Alabama at Birmingham May 27 2021 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Tags: buy Carboplatin (NSC 241240) | Carboplatin (NSC 241240) supplier | purchase Carboplatin (NSC 241240) | Carboplatin (NSC 241240) cost | Carboplatin (NSC 241240) manufacturer | order Carboplatin (NSC 241240) | Carboplatin (NSC 241240) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID